[Osteoclast-activating factors (OAF)].
Sato
Kanji
K
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University.
D015415:Biomarkers / Q000097:blood; D001862:Bone Resorption / Q000175:diagnosis*; D002352:Carrier Proteins / Q000097:blood* / Q000502:physiology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008562:Membrane Glycoproteins / Q000097:blood* / Q000502:physiology; D009101:Multiple Myeloma / Q000175:diagnosis; D010010:Osteoclasts / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis*; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000097:blood; D018124:Receptors, Tumor Necrosis Factor; D012995:Solubility; D013048:Specimen Handling
D015415:Biomarkers; D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human